Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2002.421 | Analgesic Efficacy and Pre-emptive Analgesia of Parecoxib Sodium in Gynaecological Surgery | Dr. Lim Huey Sing |
| 2005.207 | Analgesic Efficacy and Pharmacokinetic of Ropivacaine Continuous Wound Instillation Following Hepatic Resection | Dr. Chan K.C. Simon |
| 2007.169 | Analgesic Effects of Auricular Transcutaneous Electrical Nerve Stimulation After Open Hysterectomy | Mr. Tsang Hin Cheung |
| 2007.469 | Anaesthesia-related Complication in Adult Passive Smokers | Professor LEE Anna |
| 2006.358 | Anaesthesia Related Mortality and Morbidity in Year 2000 to 2005 | CHAN TV Matthew |
| 2007.456 | An Uncontrolled Observational Study to Monitor Vascular Access on Haemodilaysis Patients in One Single Centre | RN Poon Ka Lai |
| 2015.398 | An ten-year retrospective review of the medical management of tubal ectopic pregnancy with methotrexate |
Dr. WONG Lo 黃露 |
| 2024.544 | An state-of-art OlinkⓇ proteomics approach for preeclampsia-specific biomarker discovery in high risk preeclampsia women | Prof. LAU So Ling |
| 2015.712 | An qualitative exploratory study on illness experience of people living with Parkinson’s Disease |
Miss. KWOK Yan Yan 郭欣欣 |
| 2015.416 | An Outcome study of hypnotherapy for patients with irritable bowel syndrome (IBS): A randomized controlled trial |
Prof. WU Justin Che Yuen 胡志遠 |
| 2008.074 | An Outcome Model of Personalized Medicine by Genetic Testing for Warfarin Therapy | Prof You Joyce |
| 2005.243 | An Outcome Evaluation Study of Postnatal Depression Early Intervention Program | LEE Tak Shing Dominic |
| 2018.320 | An Oral Exercise Training Software for Elders in Hong Kong |
Prof. LEE Kathy Yuet Sheung 李月裳 |
| 2011.383 | An Optimization of Sourcing, Culturing and Preservation Procedures for Development of Mesenchymal Stem Cell Banking | Prof. LI Gang |
| 2010.248 | An Optimization of Sourcing, Culturing and Preservation Procedures for Development of Adult Stem Cell Banking | Prof. LI Gang |
| 2004.023 | An Opinion Survey on the Knowledge of Dementia in Chinese Caregiver of Patients with Dementia | LAM Chiu Wa Linda |
| 2012.321 | An opinion Survey among frail elderly patients and their carers regarding their opinion about self-financed community care services | Dr MA HON MING |
| 2002.396 | An Open, Randomised, Comparative, Multicentre Phase IIIb-IV Trial of the Efficacy and Safety of Ketek (Telithromycin) 8000mg Once Daily Versus other Usually Prescribed Anti-bacterials in Treating Outpatients with Mild to Moderate Community Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis and Acute Sinusitis | Prof. Tong CF Michael |
| 2012.383 | An open-labelled study to investigate Deep Brain Stimulation as treatment for medically refractory epilepsy | Prof. POON Wai Sang |
| 2011.382 | An Open-Label, Single-arm. Phase I study of AEB071 (a Protein Kinase C Inhibitor) in Patients with CD79-mutant Diffuse Large B-Cell Lymphoma | Dr Wong Siu Ming, Raymond |
| 2013.608 | An open-label, single-arm, Phase Ib/II study of AEB071 (a protein kinase C inhibitor) and everolimus (mTOR inhibitor) in patients with CD79-mutant or ABC subtype diffuse large B-cell lymphoma | Dr. WONG Raymond Siu Ming |
| 2009.309 | An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed / Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Transplantation | Dr. WONG Raymond Siu Ming |
| 2019.158 | An Open-Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor-Naive or Have Not Recently Received Complement Inhibitor Therapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2007.447 | An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin(CMC-544) Administered in Combination with Rituximab Compared to A Defined Investigator | Dr. Lei Ieng Kit, Kenny |
| 2012.150 | An Open-Label, Randomized, Phase 2 Study to Access the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma | Dr. Wong Siu Ming Raymond |
| 2007.200 | An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Prof. Mok S.K. Tony |
| 2008.099 | An Open-Label, Randomized, Multicenter, Parallel-group study to Demonstrate Correction of Anemia Using Once Every Four Weeks Subcutaneous Injections of RO0503821 in Patients with Chronic Kidney Disease Who are not on Dialysis | Prof. Kong Alice Pik-Shan |
| 2003.265 | An Open-Label, Randomized, Multi-Centre, Phase IIIb/IV, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects with Type IIa and IIb Hypercholesterolaemia | Prof. Brian Tomlinson |
| 2015.351 | An open-label, randomized, multi-center, single dose, two-period, two-sequence crossover study to investigate the bioequivalence of Peginterferon (PEG-IFN) alfa-2a benzyl alcohol-free formulation versus the reference market formulation following subcutaneous administration via prefilled syringe in healthy Chinese subjects |
Dr. OZAKI Risa Not applicable |
| 2010.563 | An open-label, randomized, multi-center, phase II study to compare the safety and efficacy of TKI258 versus sorafenib as first-line treatment in adult patients with advanced hepatocellular carcinoma | Assistant Professor Chan Lam, Stephen |
| 2020.055 | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies | Dr. POON Darren Ming Chun |
| 2024.096 | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer | Prof. YEO Winnie |
| 2010.201 | An Open-label, Randomized Phase 3 Study of Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC) | Prof. Yeo Winnie |
| 2020.591 | AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2005.339 | An Open-Label, Phase II Trial of Patupilone (EPO906) as Monotherapy to Evaluate Activity of Patupilone in Patients with Advanced Unresectable and/ or Metastatic Hepatocellular Carcinoma (HCC) | Prof. Mok S.K. Tony |
| 2023.654 | An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations | Dr. LI Molly Siu Ching |
| 2007.199 | An Open-Label, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) | Prof. Yeo Winnie |
| 2024.319 | An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Dr. LOONG Herbert Ho Fung |
| 2009.573 | An Open-label, Phase 1 Study of R-CVP or R-GDP in Combination With Inotuzumab Ozogamicin in Subjects With CD22-Positive Non-Hodgkin’s Lymphoma | Prof Cheng Gregory |
| 2021.501 | An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (BIIB098) in Chinese and Caucasian Adult Healthy Participants |
Dr. LUK Andrea On Yan 陸安欣 |
| 2011.468 | An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Adult Healthy Volunteers | Professor Tomlinson Brian |
| 2018.471 | An Open-label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of PEGCETACOPLAN in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2006.347 | An Open-Label, Multicenter, Randomized Study of Combination Therapy with Oral Telbivudine Plus Adefovir Dipivoxil Versus Adefovir Dipivoxil Alone in HBeAg-Positive Patients with Chronic Hepatitis B Who are Lamivudine Resistant | Prof. Chan L.Y. Henry |
| 2022.075 | An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2016.493 | An Open-Label, Multicenter, Phase 1 Study with Expansion Cohorts of Ramucirumab or Necitumumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer after Progression on First-Line EGFR TKI Therapy |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2024.425 | An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors | Dr. LOONG Herbert Ho Fung |
| 2016.076 | An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2008.095 | An Open-Label, Multicenter, Follow-up Trial to Evaluate Long-Term Safety and Efficacy of Brivaracetam (ucb 34714) Used as Adjunctive Treatment at A Flexible Dose Up to A Maximum of 200 mg/ day in Subjects Aged 16 Years or Older Suffering From Epilepsy | Dr. KWAN Patrick |
| 2011.539 | An Open-Label, Multicenter, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older with Epilepsy | Dr. Kwan Patrick |
| 2012.419 | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Dr. WONG Raymond Siu Ming |
Page 207 of 265.